• 8:30 - 18:00 M-T / 8.30 - 15.00 F

Histocell y Cardiva firman un acuerdo para la distribución del producto Reoxcare en todo el territorio nacional

Print

La biofarmacéutica vasca Histocell y el Grupo Cardiva unen sus fuerzas para introducir el innovador producto sanitario para la cura de heridas Reoxcare en todo el sistema sanitario español.

La empresa biofarmacéutica vasca Histocell, especializada en medicina regenerativa, ha desarrollado y fabrica Reoxcare, tratamiento antioxidante de ingredientes naturales para la cura de heridas crónicas, tras años de investigación en el estrés oxidativo.

Continue Reading

Histocell successfully completes the clinical safety phase of its cell therapy drug HC016 for the treatment of acute respiratory distress caused by COVID-19

Print

This is the Phase I clinical trial of the cell therapy drug HC016 developed by Histocell, which is being carried out at the Hospital de Cruces (Bilbao), in Spain. The objective of this trial is to offer a treatment to help overcome Acute Respiratory Distress Syndrome, the most serious complication caused by COVID-19 and the main cause of death from the disease. Histocell is among the group of companies that is working on cell therapies worldwide for this disease, with a patented and unique technology.

Continue Reading

Histocell join forces with seven companies in the Bio-Health area to launch the IMABI project

Print

Eight Basque companies, as well as various agents of the Basque Science, Technology and Innovation Network come together to research and develop new materials and biofunctional devices. The aim of this project is to promote intelligent specialisation and competitiveness of the Basque industrial fabric in the biomedical field.

Continue Reading

Histocell present at the 30th edition of EWMA 2020 VIRTUAL

Print

The annual meeting of the European Wound Management Association (EWMA) held between the 18TH and the 19TH of November 2020 has, like every year, various speakers and experts in the area of sciences, more specifically, on wound healing treatment.

Continue Reading

Histocell starts a clinical trial with its cell therapy drug HC016 in patients with ARDS due to COVID-19

Print

The most serious complication of COVID-19 infection is Acute Respiratory Distress Syndrome (ARDS). More than 40% of seriously hospitalised patients develop ARDS, and about 50% with moderate-severe ARDS die because of it. Taking into account the proven safety and efficacy of mesenchymal cells in diseases that occur with a process of exacerbated inflammation, several groups, including the one led by Dr. Dongcheng Wu in Wuhan (China), have focused their efforts on cell treatment for critically ill COVID-19 patients with promising results.

Continue Reading

Histocell signs an agreement with Bfactory Italia for the distribution of Reoxcare

Print

The company Bfactory Italia, specialised in the distribution of international medical devices in the Italian market, focuses its business in the search of natural products that improve people's lives.

For this reason, they have started with the distribution of Reoxcare line for wound healing.

Reoxcare, thanks to its innovative character and its components of natural origin, is a great example of the type of products the company wants to have in its porfolio.

Fbactory Italia website

Histocell Headquarters

Parque Tecnológico 801A, 2º
48160 Derio
Bizkaia - Spain

+34 94 656 7900
info@histocell.com

Histocell Factory

Polígono Sasine. Patakon s/n
48195 Larrabetzu
Bizkaia - Spain

+34 94 656 7900
info@histocell.com

Our mision

We develop new advanced therapy medicinal products, medical devices and dermocosmetics to improve people's quality of life.

Copyright © Histocell